Shared on 01 Nov 25
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.
Shared on 17 Oct 25
Fair value Increased 4.08%Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.
Shared on 03 Oct 25
Fair value Increased 2.08%Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.
Shared on 10 Aug 25
Fair value Increased 9.71%Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.
Shared on 08 May 25
Fair value Increased 2.41%Sterigenics And Nelson Labs Will Capture New Opportunities
Shared on 30 Apr 25
Fair value Decreased 2.00%Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 3.77%Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 1.74%Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 2.87%Sterigenics And Nelson Labs Will Capture New Opportunities
Shared on 26 Mar 25
Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Increased 3.01%Sterigenics And Nelson Labs Will Capture New Opportunities
AnalystConsensusTarget has increased revenue growth from 4.2% to 4.9%, increased profit margin from 11.6% to 16.2% and decreased future PE multiple from 39.3x to 26.6x.